LLY

1,094.64

-3.09%↓

JNJ

227.39

-1.66%↓

ABBV

217.23

-0.49%↓

UNH

377.5

-2.18%↓

MRK

118.74

-1.48%↓

LLY

1,094.64

-3.09%↓

JNJ

227.39

-1.66%↓

ABBV

217.23

-0.49%↓

UNH

377.5

-2.18%↓

MRK

118.74

-1.48%↓

LLY

1,094.64

-3.09%↓

JNJ

227.39

-1.66%↓

ABBV

217.23

-0.49%↓

UNH

377.5

-2.18%↓

MRK

118.74

-1.48%↓

LLY

1,094.64

-3.09%↓

JNJ

227.39

-1.66%↓

ABBV

217.23

-0.49%↓

UNH

377.5

-2.18%↓

MRK

118.74

-1.48%↓

LLY

1,094.64

-3.09%↓

JNJ

227.39

-1.66%↓

ABBV

217.23

-0.49%↓

UNH

377.5

-2.18%↓

MRK

118.74

-1.48%↓

Home・Lista de Ações・CytoSorbents Corp

CytoSorbents Corp

Fechado

SetorSaúde

0.48 4.35

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

0.43

Máximo

0.49

Indicadores-chave
By Trading Economics
Rendimento	368K -5.1M
Vendas	-370K 8.9M
EPS	-0.08
Margem de lucro	-57.863
Funcionários	129
EBITDA	648K -3M

Recomendações
By TipRanks
Recomendações	Neutro
Previsão para 12 meses	+53.06% upside

Dividendos
By Dow Jones
Próximos Ganhos	6 de ago. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	-11M 29M
Abertura anterior	-3.87
Fecho anterior	0.48

Sentimento de Notícias

By Acuity

46%

54%

142 / 344 Ranking em Healthcare

CytoSorbents Corp Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

28 de mai. de 2026, 22:47 UTC

Ganhos

Costco 3Q Sales Rise as Value Offerings Draw Pressured Consumers -- Update

28 de mai. de 2026, 20:45 UTC

Ganhos

Costco 3Q Profit Rises as Value Offerings Draw Pressured Consumers

28 de mai. de 2026, 23:43 UTC

Conversa de Mercado

Nikkei May Rise on Hopes for U.S.-Iran Peace Deal -- Market Talk

28 de mai. de 2026, 23:39 UTC

Conversa de Mercado

Gold Edges Lower as Traders Assess Potential U.S.-Iran Deal -- Market Talk

28 de mai. de 2026, 23:31 UTC

Conversa de Mercado

KMD Could Realize Value From Selling Either Oboz or Rip Curl -- Market Talk

28 de mai. de 2026, 23:17 UTC

Conversa de Mercado

Mainfreight Steering Its Way Out of Tough Period -- Market Talk

28 de mai. de 2026, 23:02 UTC

Conversa de Mercado

Costco Has Started Submitting Tariff Refund Claims -- Market Talk

28 de mai. de 2026, 22:41 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

28 de mai. de 2026, 22:41 UTC

Conversa de Mercado

MongoDB Still Getting More Growth From Established Customers Than AI -- Market Talk

28 de mai. de 2026, 22:37 UTC

Conversa de Mercado

Aquisições, Fusões, Aquisições de Empresas

M&A-Related Insurance Payments In North America Rise -- Market Talk

28 de mai. de 2026, 22:04 UTC

Aquisições, Fusões, Aquisições de Empresas

CN: Surface Transportation Board Was Right to Freeze the UP-NS Merger and Demand More Info

28 de mai. de 2026, 22:04 UTC

Aquisições, Fusões, Aquisições de Empresas

CN: This Confirms What CN and Many Stakeholders Have Said All Along, UP and NS Still Have Not Submitted a Credible Case to Support Their Proposed Merger >CNI

28 de mai. de 2026, 21:12 UTC

Ganhos

Aquisições, Fusões, Aquisições de Empresas

Synopsys Was the Worst S&P 500 Stock Thursday Despite Earnings Beat With AI and Merger in Focus -- Barrons.com

28 de mai. de 2026, 21:00 UTC

Ganhos

Dell Stock Soars on Blowout Earnings. The Outlook Bests Analysts by $20 Billion. -- Barrons.com

28 de mai. de 2026, 20:57 UTC

Ganhos

Dell Stock Soars on Blowout Earnings -- Barrons.com

28 de mai. de 2026, 20:55 UTC

Ganhos

Costco Wholesale Sees a Mixed Quarter, Misses Earnings Estimates -- Barrons.com

28 de mai. de 2026, 20:50 UTC

Conversa de Mercado

Tech, Media & Telecom Roundup: Market Talk

28 de mai. de 2026, 20:50 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

28 de mai. de 2026, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

28 de mai. de 2026, 20:48 UTC

Ações em Alta

Stocks to Watch Recap: Snowflake, Union Pacific, Hormel Foods -- WSJ

28 de mai. de 2026, 20:34 UTC

Ganhos

One of the S&P 500's Highest Dividends Looks Even Better Now -- Barrons.com

28 de mai. de 2026, 20:31 UTC

Ganhos

Li and XPeng Both Miss Earnings Estimates. One Chinese EV Maker's Stock Is Rising. -- Barrons.com

28 de mai. de 2026, 20:28 UTC

Ganhos

Best Buy's 5% Dividend Yield Looks Even Better After Earnings -- Barrons.com

28 de mai. de 2026, 20:26 UTC

Ganhos

Dell Stock Soars on Blowout Earnings -- Barrons.com

28 de mai. de 2026, 20:20 UTC

Ganhos

Costco 3Q Membership Fees $1.37B

28 de mai. de 2026, 20:20 UTC

Ganhos

Costco 3Q Net Sales $69.15B

28 de mai. de 2026, 20:19 UTC

Ganhos

Costco 3Q Adj Same-Store Sales, Which Excludes Impacts From Gas Prices and Foreign Exchange, Rose 6.6% >COST

28 de mai. de 2026, 20:19 UTC

Ganhos

Costco 3Q Adjusted Digitally-Enabled Sales Rose 20.8% >COST

28 de mai. de 2026, 20:17 UTC

Ganhos

Costco 3Q Digitally-Enabled Sales Rose 21.5% >COST

28 de mai. de 2026, 20:17 UTC

Ganhos

Costco 3Q Same-Store Sales Up 9.8% >COST

Comparação entre Pares

Variação de preço

CytoSorbents Corp Previsão

Preço-alvo

By TipRanks

53.06% parte superior

Previsão para 12 meses

Média 0.75 USD 53.06%

Máximo 0.75 USD

Mínimo 0.75 USD

Com base em 1 analistas de Wall Street que oferecem metas de preço de 12 meses para CytoSorbents Corp - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Neutro

1 ratings

Comprar

Manter

Vender

Com base em 1 analistas que deram avaliações de ações para CytoSorbents Corp - Dist nos últimos 3 meses.

Sentimento

By Acuity

142 / 344 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre CytoSorbents Corp

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it develops BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove drugs and chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.